Lower GI 2017

ART: room for dose escalation ?

3Gy/fr 3.5 4 dadapt

- Potential approach for future trials aimed to avoid surgery ?

54Gy 60 66 EQD2(T)

52Gy 57 63 EQD2(OAR)

12% ? ? G3 GI

29%* ? ? pCR+cCR

*average rate of pCR from randomized trials with oxaliplatin: 18%

Appelt 2012

- Potentials in exploring protocols of watchful waiting ? (Appelt 2015, Renehan 2016)